This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Resistance to targeted therapies in acute myeloid leukemia
Clinical & Experimental Metastasis Open Access 01 November 2022
-
Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia
Journal of Hematology & Oncology Open Access 28 January 2020
-
Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms
Nature Communications Open Access 16 January 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood 2009; 114: 2984–2992.
von Bubnoff N, Engh RA, Aberg E, Sanger J, Peschel C, Duyster J . FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro. Cancer Res 2009; 69: 3032–3041.
von Bubnoff N, Rummelt C, Menzel H, Sigl M, Peschel C, Duyster J . Identification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib. Leukemia 2010; 24: 1523–1525.
Cools J, Mentens N, Furet P, Fabbro D, Clark JJ, Griffin JD et al. Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia. Cancer Res 2004; 64: 6385–6389.
Heidel F, Solem FK, Breitenbuecher F, Lipka DB, Kasper S, Thiede MH et al. Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. Blood 2006; 107: 293–300.
Kancha RK, Grundler R, Peschel C, Duyster J . Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations. Exp Hematol 2007; 35: 1522–1526.
Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature 2012; 485: 260–263.
Moore AS, Faisal A, de Castro DG, Bavetsias V, Sun C, Atrash B et al. Selective FLT3 inhibition of FLT3-ITD(+) acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns. Leukemia 2012; 26: 1462–1470.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Albers, C., Leischner, H., Verbeek, M. et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia 27, 1416–1418 (2013). https://doi.org/10.1038/leu.2013.14
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2013.14
This article is cited by
-
Blockade of de novo pyrimidine biosynthesis triggers autophagic degradation of oncoprotein FLT3-ITD in acute myeloid leukemia
Oncogene (2023)
-
Perspectives and challenges of small molecule inhibitor therapy for FLT3-mutated acute myeloid leukemia
Annals of Hematology (2023)
-
Resistance to targeted therapies in acute myeloid leukemia
Clinical & Experimental Metastasis (2023)
-
Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia
Journal of Hematology & Oncology (2020)
-
Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms
Nature Communications (2019)